Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Giparmen	NCIT_C74115
Ruzadolane	NCIT_C74116
Gavestinel	NCIT_C74117
Anesthetic Agent	NCIT_C245	[A pharmacological agent that acts in a reversible fashion and can be applied either locally or systemically to cause a partial or total loss of sensation and pain or to induce unconsciousness.]
Fospropofol Disodium	NCIT_C74118
Bolasterone	NCIT_C74111
Microbiology Test	NCIT_C49188	[A laboratory procedure to detect microorganisms in a sample.]
Oxymesterone	NCIT_C74112
Primary Key	NCIT_C49189	[The attribute selected as being most important for uniquely identifying a body of information (an entity, object or record).]
Key	NCIT_C46002	[A value used to identify a record in a database.]
Alimadol	NCIT_C74113
Acequinoline	NCIT_C74114
Loop Diuretic	NCIT_C49184	[Any agent belonging to the class of loop diuretics. Loop diuretics block and inhibit the function of the sodium-potassium-chloride (Na+, K+, Cl-) cotransporter system in the thick ascending limb of the loop of Henle, thereby inhibiting the reabsorption of sodium, potassium, and chloride ions. This leads to an increase in the excretion of sodium, potassium, chloride, calcium, magnesium, ammonium and water.]
Potassium-Sparing Diuretic	NCIT_C49186	[Any diuretic agent that produces diuresis without increasing potassium excretion. Potassium sparing diuretics are generally either aldosterone antagonists and thus prevent the aldosterone-mediated promotion of sodium and water retention, or are epithelial sodium channel blockers and prevent the exchange of potassium for sodium in the distal convoluted tubule. These agents cause diuresis without increasing potassium secretion and thus do not cause hypokalemia.]
Cioteronel	NCIT_C74119
XIAP Antisense Oligonucleotide AEG35156	NCIT_C49180	[A second-generation synthetic antisense oligonucleotide with potential antineoplastic activity. AEG35156 selectively blocks the cellular expression of X-linked inhibitor of apoptosis protein (XIAP), a pivotal inhibitor of apoptosis that is overexpressed in many tumors. This agent reduces total levels of XIAP in tumor cells, working synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. XIAP interferes with both the intrinsic and extrinsic program-death signaling pathways, which may render tumor cells resistant to apoptosis.]
Inosine Monophosphate Dehydrogenase Inhibitor AVN944	NCIT_C49181	[An orally available, synthetic small molecule with potential antineoplastic activity. AVN944 inhibits inosine monosphosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine triphosphate (GTP), a purine molecule required for DNA and RNA synthesis. Inhibition of IMPDH deprives cancer cells of GTP, resulting in disruption of DNA and RNA synthesis, inhibition of cell proliferation, and the induction of apoptosis. AVN944 appears to have a selective effect on cancer cells in that deprivation of GTP in normal cells results in a temporary slowing of cell growth only. IMPDH is overexpressed in some cancer cells, particularly in hematological malignancies.]
Inosine Monophosphate Dehydrogenase Inhibitor	NCIT_C2087	[Any substance that inhibits inosine monophosphate dehydrogenase, an enzyme that catalyzes the conversion of inosine monophosphate to xanthosine monophosphate, the rate-limiting step in the de novo biosynthesis of guanine nucleotides. Inhibition of inosine monophosphate dehydrogenase can lead to inhibition of cell proliferation.]
Immunomodulatory Oligonucleotide HYB2055	NCIT_C49182	[A second generation synthetic oligonucleotide with immunomodulatory and potential antineoplastic activities. HYB2055 consists of unmethylated CpG dinucleotide motifs that are present abundantly in bacterial and parasitic DNA, and a novel DNA structure, called an immunomer that contributes to metabolic stability of the agent. Upon infections, CpG-containing DNA released from pathogenic organisms triggers host immune responses, which are mediated by the action of intracellular toll-like receptor 9 (TLR9), a pattern recognition receptor. This agent mimics bacterial DNA and selectively activates TLR9, thereby initiating immune signaling pathways, and leading to activation of B-cells and dendritic cells and induction of Th1-type cytokine production.]
Single Agent Systemic Chemotherapy	NCIT_C15756	[Systemic chemotherapy with a single agent regimen. All routes of administration are acceptable as long as the agent is intended for systemic therapy.]